Cencora, Inc. (NYSE:COR) Shares Sold by Blue Grotto Capital LLC

Blue Grotto Capital LLC reduced its position in shares of Cencora, Inc. (NYSE:COR) by 19.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 95,000 shares of the company’s stock after selling 22,876 shares during the period. Cencora accounts for approximately 4.4% of Blue Grotto Capital LLC’s holdings, making the stock its 10th biggest position. Blue Grotto Capital LLC’s holdings in Cencora were worth $18,281,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Tilia Fiduciary Partners Inc. grew its stake in shares of Cencora by 321.2% in the 2nd quarter. Tilia Fiduciary Partners Inc. now owns 139 shares of the company’s stock valued at $27,000 after purchasing an additional 106 shares during the period. Harbour Investments Inc. boosted its position in shares of Cencora by 61.8% in the 1st quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Creative Financial Designs Inc. ADV increased its stake in Cencora by 50.9% in the second quarter. Creative Financial Designs Inc. ADV now owns 175 shares of the company’s stock valued at $34,000 after purchasing an additional 59 shares in the last quarter. Cascade Investment Advisors Inc. bought a new position in Cencora during the first quarter worth about $32,000. Finally, Altshuler Shaham Ltd bought a new stake in Cencora in the 2nd quarter valued at $40,000. 93.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In related news, CEO Steven H. Collis sold 25,000 shares of the stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $185.08, for a total transaction of $4,627,000.00. Following the sale, the chief executive officer now owns 257,967 shares of the company’s stock, valued at approximately $47,744,532.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Cencora news, EVP Gina Clark sold 10,695 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $187.00, for a total value of $1,999,965.00. Following the completion of the transaction, the executive vice president now owns 16,038 shares of the company’s stock, valued at approximately $2,999,106. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Steven H. Collis sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $185.08, for a total value of $4,627,000.00. Following the transaction, the chief executive officer now directly owns 257,967 shares in the company, valued at $47,744,532.36. The disclosure for this sale can be found here. Insiders own 20.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on COR shares. StockNews.com started coverage on Cencora in a report on Sunday, October 1st. They set a “strong-buy” rating on the stock. TheStreet raised Cencora from a “c” rating to a “b” rating in a research note on Monday, October 9th. TD Cowen increased their price target on Cencora from $205.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, August 7th. Evercore ISI upped their target price on Cencora from $210.00 to $225.00 in a report on Wednesday, October 11th. Finally, Morgan Stanley boosted their price target on shares of Cencora from $176.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $196.08.

Cencora Stock Performance

Cencora stock traded down $0.74 during trading on Monday, hitting $196.83. The stock had a trading volume of 331,737 shares, compared to its average volume of 1,392,815. The stock has a market cap of $39.80 billion, a price-to-earnings ratio of 23.16, a price-to-earnings-growth ratio of 1.72 and a beta of 0.53. The stock’s 50 day moving average is $186.05 and its two-hundred day moving average is $180.22. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 6.22. Cencora, Inc. has a 1 year low of $147.48 and a 1 year high of $198.98.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 27th. Investors of record on Monday, November 13th will be paid a dividend of $0.51 per share. This is a boost from Cencora’s previous quarterly dividend of $0.49. This represents a $2.04 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Friday, November 10th. Cencora’s dividend payout ratio is presently 23.92%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.